Background {#Sec1}
==========

Candidaemia is the most common fungal disease among hospitalised patients worldwide and is the fourth to tenth most common bloodstream infection (BSI) in most population-based studies \[[@CR1], [@CR2]\]. Candidaemia is associated with significant morbidity and mortality \[[@CR3]\]. The main risk factors for candidaemia include critical illness, a long intensive care unit (ICU) length of stay, haematologic malignant disease, solid-organ transplantation, solid-organ tumours, low birth weight in neonates and preterm infants, broad-spectrum antimicrobial agent use, central venous catheterization (CVC), total parenteral nutrition, haemodialysis, abdominal surgery, and aggressive chemotherapy \[[@CR1]\]. With the increase in related research, reports have shown that the incidence of candidaemia is age-specific, with maximum rates observed in those with older age (over 65 years) \[[@CR1], [@CR4], [@CR5]\].

More than 40 Candida species can cause candidaemia in humans \[[@CR6]\]. Five species of Candida (*Candida albicans*, *Candida glabrata*, *Candida parapsilosis*, *Candida tropicalis* and *Candida krusei*) are the most common species and account for more than 90% of all the isolates \[[@CR2]\]. The variability in the relative proportions of Candida isolates has been associated with clinical condition or risk factors such as age, underlying comorbidities, the extensive use of antifungal agents and geography. *Candida albicans* is the primary cause of candidaemia and one of the most common species in many countries, *Candida glabrata* is the second or third most common species in the USA and Europe, and *Candida parapsilosis* is predominant in neonates in South America, southern Europe and Asia \[[@CR2]\]. The global incidence of candidaemia varies from 0.3 to 5 per 1000 admissions according to geographical region, local epidemiology, age and other factors \[[@CR7]\]; the 30-day mortality among all patients with candidaemia has been reported to be between 22 and 70% \[[@CR8]\], and the cost of candidaemia treatment has been reported to be US \$40,000 per patient \[[@CR1], [@CR9], [@CR10]\].

In China, the epidemiology of candidaemia varies widely among different areas \[[@CR11]\]. Epidemiological surveillance of candidaemia has focused on ICUs and single centres in China, and national surveillance systems are usually absent. Most of the existing epidemiological surveillance of candidaemia has focused on adults or children, and little information about general populations (including neonates, children and adults) is known. Therefore, in the present study, we performed a seven-year retrospective study to evaluate the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among all inpatients in a tertiary teaching hospital in China.

Methods {#Sec2}
=======

Patient data collection {#Sec3}
-----------------------

We conducted a retrospective observational study of electronic laboratory records. The fungal specimen data were collected from inpatients with candidaemia in the Affiliated Hospital of Southwest Medical University (Luzhou, China), which is a 3200-bed tertiary care teaching hospital with 43 wards and approximately 120,000 annual admissions, from January 2013 to December 2019. The diagnostic criteria of candidaemia were based on the guidelines for the diagnosis and treatment of Candidiasis: the expert consensus issued by the Chinese Medical Association \[[@CR12]\]; these criteria were also in accordance with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)\* guidelines for the diagnosis and management of *Candida* diseases 2012 \[[@CR13], [@CR14]\] and the Infectious Diseases Society of America (IDSA) Guidelines for the Management of Candidiasis: 2016 Update \[[@CR15]\]. For each patient, only the first episode was included in our analysis. Patient cultures with two or more *Candida* species were excluded from the analysis, and all data were collected from electronic medical records. The following data were retrospectively collected from all patients: demographic characteristics, underlying comorbidities, *Candida* species, susceptibility to antifungal agents and mortality. Data on the following risk factors associated with candidaemia were also collected: gestational age and weight of neonates, indwelling central vascular catheter, mechanical ventilation, systemic corticosteroid treatment (a dose equivalent to prednisone 10 mg/d for at least 14 days), total parenteral nutrition, chemotherapy, abdominal surgery, ICU admission, neutropenia (absolute neutrophil count \< 500 cells/μl), concomitant bacterial infections, septic shock, haemodialysis, broad-spectrum antibiotic use and treatment with antifungal agents. The study protocol was approved by the ethics committee of the hospital (Project No. KY2020043). The need for informed consent was waived by the Clinical Research Ethics Committee.

Microorganism identification and antifungal susceptibility {#Sec4}
----------------------------------------------------------

According to the manufacturer's instructions, blood was inoculated into both aerobic and anaerobic BacT/AlerT 3D vials (Bruker Diagnostics Inc., USA). All positive cultures were manually sampled and inoculated onto CHROMagar *Candida* medium (CHROMagar Company, France) to ensure viability and purity. The identification of all species was confirmed by a MicroScan WalkAway 96 Plus System (Siemens, Germany) and Microflex LT (Bruker Diagnostics Inc., USA) matrix-assisted laser-desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) system.

Antifungal susceptibility tests for fluconazole (FCA), itraconazole (ITR), voriconazole (VRC), flucytosine (5-FC) and amphotericin B (AMB) were performed for all *Candida* strain isolates by using an ATB FUNGUS 3 kit (bioMérieux, France). The minimal inhibitory concentrations (MICs) of the antifungal agents were judged by visualization in our laboratory according to the manufacturer's instructions. The quality control strains were *C. parapsilosis* ATCC 22019 and *C. krusei* ATCC 6258. The results were interpreted using the Clinical and Laboratory Standards Institute M27-A3 microbroth dilution method.

Statistical analyses {#Sec5}
--------------------

The data were analysed using Microsoft Excel (version 2016, Redmond, USA) and IBM SPSS software version 24 for Windows (IBM, Armonk, USA). Categorical data were compared using chi-square or Fisher's exact tests. Continuous data were analysed using Student's t-test or the Mann-Whitney U test. Multivariable logistic regression analysis was performed to identify independent predictors of candidemia and 30-day hospital mortality. Biologically plausible variables with a value of *P* \< 0.1 according to the univariate analyses were included in the multiple logistic regression model. Statistical significance was determined using two-tailed tests, and *P* \< 0.05 was considered statistically significant.

Results {#Sec6}
=======

A total of 201 distinct candidaemia episodes were identified during our study period. The median age was 65 years (range 1 day − 92 years), and 114 patients (56.7%) were male. Most candidaemia episodes were diagnosed in medical wards (89, 44.3%), followed by ICUs (46, 22.9%), paediatric wards (35, 17.4%) and surgical wards (31, 15.4%). Most of the patients had one or more comorbidities. Pulmonary infection (49.8%), chronic/acute renal failure (45.3%) and cardiovascular disease (42.8%) were the most common underlying comorbidities, followed by neurological diseases (38.8%), diabetes mellitus (29.9%), respiratory dysfunction (28.9%), gastrointestinal pathologies (28.9%) and chronic/acute liver disease (24.4%). Moreover, the most common underlying conditions documented prior to candidaemia were prior exposure to broad-spectrum antibiotics (89.1%), treatment with antifungal agents (56.7%), concomitant bacterial infections (54.7), total parenteral nutrition (47.3%), mechanical ventilation (43.3%), ICU/paediatric ICU (PICU)/neonatal ICU (NICU) admission (40.3%) and CVC (38.3%). In total, 53 (26.4%, 53/201) patients had received previous antifungal treatment, and paediatric patients accounted for 71.4% (25/35) of the total. The underlying comorbidities in adult patients were significantly worse than those in paediatric patients, but the number of underlying conditions in paediatric patients were significantly higher than those in adult patients, and the difference was statistically significant (*P* \< 0.05). FCA was the most frequently used empirical antifungal treatment (60/114, 52.6%). The demographic and clinical characteristics of the patients are summarized in Table [1](#Tab1){ref-type="table"} and Table [2](#Tab2){ref-type="table"}. Table 1Distribution and incidence of Candida species*Candida* speciesTotal*C. albicansC. glabrataC. tropicalisC. parapsilosisC. kruseiothers*(*n* = 201)\
100.0%(*n* = 81)\
40.3%(*n* = 73)\
36.3%(*n* = 28)\
13.9%(*n* = 8)\
4.0%(*n* = 6)\
3.0%(*n* = 5)\
2.5%Distribution n(%) Paediatric patients (≤16 years)35(17.4)16(45.7)18 (51.4)0 (0)0 (0)0 (0)1 (2.9) 0--28 days32(15.9)16(50.0)15(46.9)0 (0)0 (0)0 (0)1 (3.1) 29 days - 1 year1(0.5)0 (0)1(100.0)0 (0)0 (0)0 (0)0 (0) 2--16 years2(1.0)0 (0)2(100.0)0 (0)0 (0)0 (0)0 (0) Adult patients (\> 16 years)166(82.6)65(39.2)55(33.1)28(16.9)8(4.8)6(3.6)4(2.4) 17--49 years52 (25.9)21(40.4)19 (36.5)7(13.5)1(1.9)3(5.8)1 (1.9) 50--65 years56 (27.9)11 (19.6)23 (41.1)14 (25.0)5(8.9)1(1.8)2 (3.6)  \> 65 years58(28.8)33(56.9)13(22.4)7(12.1)2(3.4)2(3.4)1(1.7)Gender Male114 (56.7)44 (38.6)39 (34.2)19 (16.7)6(5.3)2 (1.7)4 (3.5) Female87 (43.3)37 (42.5)34 (39.1)9(10.3)2(2.3)4 (4.6)1 (1.1)Incidence (episodes/1000 admissions) 20130.200.060.120.010.000.010.00 20140.220.090.100.030.000.000.01 20150.270.100.120.020.000.030.00 20160.370.230.100.040.000.010.00 20170.320.100.140.070.010.000.00 20180.160.060.070.020.000.000.00 20190.260.080.040.050.050.010.03 Mean annual incidence0.260.100.090.040.010.010.01\*Others include *C. guilliermondii* (3)*, C. haemulonii* (3) and *C. inconspicua* (1)Table 2Patient characteristics and incidence (episode/1000 admission)All patientsChild patients(0-16 years)Adult patients(\> 16 years)P\*(*n* = 201)\
100.0%(*n* = 35)\
17.4%(*n* = 166)\
82.6%**Age (median, range)65 years(1 day, 92 years)1 day(1 day,5 years)61 years(18 years, 92 years)\< 0.001**Gender (male:female)114:8722:1392:740.420Length of hospital stay(days)36.9 ± 39.541.5 ± 20.930.6 ± 39.60.117Underlying comorbidities (*n*, %) Gastrointestinal perforation24 (11.9)2 (5.7)22(13.3)0.211 ***Respiratory dysfunction***^***a***^***58 (28.9)**3 (8.6)**55 (33.1)**0.004*** **Pulmonary infection100(49.8)24 (68.6)76(45.8)0.014** ***Cardiovascular disease**86 (42.8)**3(8.6)**83 (50.0)**\< 0.001*** **Neurological diseases78 (38.8)24(68.6)54 (32.5)\< 0.001** ***Gastrointestinal pathology***^***b***^***58(28.9)**2(5.7)**43 (25.9)**0.001*** Chronic/acute liver disease49(24.4)9(25.7)40(24.1)0.839 ***Chronic/acute renal failure***^***c***^***91(45.3)**9(25.7)**82 (49.4)**0.011*** Solid tumour15(7.5)0(0)15(9.0)0.065 Haematological malignancy11 (5.5)2 (5.7)9(5.4)0.697 **Congenital malformations/syndromes6(3.0)3 (8.6)3 (1.8)\< 0.001** ***Diabetes mellitus**60 (29.9)**0(0)**60 (36.1)**\< 0.001*** **Hematologic (nonmalignant)29 (14.4)10 (28.6)19 (11.4)0.009** HIV/AIDS10 (5.0)0(0)10 (6.0)0.136 Severe trauma17(8.5)2 (5.7)15 (9.0)0.521Risk factors (*n*, %) ***Presence of CVC***^***d***^***77(38.3)**7(20.0)**70(42.2)**0.014*** ***Other invasive catheters**60(29.9)**5(14.3)**55(33.1)**0.027*** **Mechanical ventilation87(43.3)21 (60.0)66(39.8)0.028** Receipt of corticosteroids^e^42 (20.9)9(25.7)33(19.9)0.440 Total parenteral nutrition95(47.3)18(51.4)77(46.4)0.587 Malnutrition55(27.4)9(25.7)46(27.7)0.810 Chemotherapy20(10.0)2 (5.7)18(10.8)0.357 **Hemodialysis30(16.9)0(0)30(18.1)0.006** ***Abdominal surgery***^***f***^***31 (15.4)**0 (0)**31 (18.7)**0.005*** **ICU/PICU/NICU81(40.3)35 (100.0)46 (27.7)\< 0.001** Neutropenia^g^16(8.0)0 (0)16(9.6)0.056 **Concomitant bacterial infections110(54.7)30 (85.7)80 (48.2)\< 0.001** Septic shock39 (19.4)3 (8.6)36(21.7)0.075 **Broad-spectrum antibiotics179 (89.1)35 (100.0)144 (86.7)0.022** **Treatment with antifungal agents114 (56.7)27(77.1)87(52.4)0.007** *C. albicans*81(40.3)16(45.7)65(39.2)0.472 ***C. glabrata*73(36.3)18(51.4)55(33.1)0.041** ***C. tropicalis**28(13.9)**0(0)**28(16.9)**0.009*** Death41(20.4)4(11.4)37(22.3)0.113Incidence(n,episodes/1000 admissions) 201314(0.20)0(0.0)14(0.24)0.248 201423(0.22)1(0.09)22(0.24)0.507 201529(0.27)6(0.53)23(0.24)0.117 **201642(0.37)12(1.07)30(0.29)0.001** **201738(0.32)12(1.06)26(0.24)\< 0.001** 201820(0.16)3(0.21)17(0.15)0.480 201935(0.26)1(0.08)34(0.27)0.252Mean annual incidence201(0.26)35(0.42)166(0.24)0.002\*Statistical results of demographic characteristics of pediatric and adult patients^a^ Includes the following diseases: chronic obstructive pulmonary disease and acute respiratory distress syndrome^b^ Includes the following diseases: cholecystitis, pancreatitis, and peritonitis^c^ Chronic/Acute renal failure is the permanent or sudden and often temporary loss of kidney function with N waste retention and hypourocrinia^d^ *CVC* central venous catheter^e^a dose equivalent to the prednisone dosage of 0.3 mg/kg/day for at least 14 days^f^ including: gastrointestinal perforations, severe acute pancreatitis and complex ventral hernia^g^ Neutropenia is the absolute neutrophil count, that is, \< 500 cells/μl

The mean annual incidence of candidaemia was 0.26/1000 admissions, including 0.42/1000 paediatric admissions (1.61/1000 neonatal admissions (age \< 28 days), 0.06/1000 infant admissions (28 days \< age \< 1 year) and 0.04/1000 child admissions (1 year \< age \< 16 years)) and 0.24/1000 adult admissions (0.09/1000 surgical admissions, 0.30/1000 medical admissions and 1.64/1000 ICU admissions). According to the Candida species, the incidence of the three most commonly isolated Candida species were as follows: *C. albicans,* 0.10/1000 admissions; *C. glabrata,* 0.09/1000 admissions; and *C. tropicalis,* 0.04/1000 admissions.

The most common species among all Candida species isolates was *C. albicans* (40.3%), followed by *C. glabrata* (36.3%), *C. tropicalis* (13.9%), *C. parapsilosis* (4.0%), *C. krusei* (3.0%) and others (2.5%). The distributions of Candida species in paediatric (\< 16 years) and adult (≥16 years) patients are shown in Table [1](#Tab1){ref-type="table"}. In patients aged 0--16 years and 49--65 years, *C. glabrata* was the predominant species (51.4 and 41.1%, respectively), but in patients aged 17--49 and \> 65 years, *C. albicans* was the main species (45.7 and 56.9%, respectively). The distribution of Candida species in paediatric, surgical, internal medicine and ICU wards is shown in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1Distribution of the fungal species according to different wards. FootNote: Others include *C. guilliermondii* (3), C. haemulonii (1) and *C. inconspicua* (1)

The results of in vitro susceptibility testing of *Candida* strain isolates are summarized in Table [3](#Tab3){ref-type="table"}. All isolates were highly susceptible to AMB (99.0%) and 5-FC (99.0%). The resistance rates of ITR, VRC and FCA were 24.9 19.4 and 18.5%, respectively. *C.tropicalis* had the highest antifungal agent resistance rate among the *Candida* species and was resistant to FCA (39.3%), ITR (39.3%) and VRC (42.9%). The activity of antifungal agents against Candida species was not significantly different in terms of satisfactory outcomes between paediatric and adult patients (*P* \> 0.05). The detailed data are shown in Table [3](#Tab3){ref-type="table"}. Table 3In vitro antifungal susceptibility testing of 201 clinical isolates into 5 antifungal agentsSpecies\
(No of isolates)Antifungal agentResistant n(%)^e^Children (35)Adults(166)totalP^c^*Candida albicans*(81)Amphotericin B000^b^--Flucytosine01(1.5)1(1.2)^b^0.618Fluconazole2(12.5)17(26.2)19(23.5)0.248Itraconazole8(50.0)22(33.8)30(37.0)^b^0.231Voriconazole4(25.0)20(30.8)24(29.6)^b^0.651*Candida glabrata*(73)Amphotericin B1(5.6)01(1.4)^b^0.078Flucytosine000^b^--Fluconazole1(5.6)5(9.1)6(8.2)0.635Itraconazole2(11.1)5(9.1)7(9.6)^b^0.801Voriconazole1(5.6)2(3.6)3(4.1)^b^0.722*C.tropicalis*(28)Amphotericin B01(3.6)1(3.6)^b^--Flucytosine01(3.6)1(3.6)^b^--Fluconazole011(39.3)11(39.3)^b^--Itraconazole011(39.3)11(39.3)^b^--Voriconazole012(42.9)12(42.9)^b^--*C. krusei*(6)Amphotericin B000--Flucytosine000--Fluconazole^a^--------Itraconazole01(16.7)1(16.7)^b^--Voriconazole01(16.7)1(16.7)^b^--All of isolates (201)Amphotericin B1(2.9)1(0.6)2(1.0)0.222Flucytosine0(0)2(1.2)2(1..0)0.513Fluconazole^a^3(8.6)33(20.6)36(18.5)0.096Itraconazole10(28.6)40(24.1)50(24.9)0.578Voriconazole5(14.3)34(20.5)39(19.4)0.400*MIC* minimal inhibitory concentration^a^Resistance rate was based on the intrinsic resistance of *C*. *krusei* and did not follow the actual MICs^b^The breakpoints of *Candida* spp. according to the manufacturer's instructions of ATB FUNGUS 3 system^c^The difference of resistance rate between children and adults was analyzed by chi square test^e^*C. parapsilosis* and others isolates (*C. guilliermondii* (3), *C. haemulonii* (1) and *C. inconspicua* (1)) were susceptible to five antifungal agents (100%), so the results were not listed

The all-cause mortality rate in the 201 patients was 20.4% (41/201). The 7-day and 30-day mortality rates were 8.5% (17/201) and 17.9% (36/201), respectively. The mortality rates of *C. albicans*, *C. glabrata*, *C. tropicalis* and *C. parapsilosis* infections were 27.2% (22/81), 16.4% (12/73), 21.4% (6/28) and 12.5% (1/8), respectively. The mortality rates for paediatric wards, medical wards, surgical wards and ICU wards were 11.4% (4/35), 22.5% (20/89), 16.1% (5/31) and 26.1% (12/46), respectively. The mortality rates for different age groups were 11.4% (4/35, 0--16 years) among paediatric patients and 22.3% (37/166(\> 16 years), 7.7% (4/52, 17--49 years), 19.6% (11/56, 50--65 years) and 37.9% (22/58, \> 65 years)) among adult patients.

The univariate predictors of poor outcomes due to candidaemia are shown in Table [4](#Tab4){ref-type="table"}. For paediatric patients with candidaemia, the variables associated with 30-day mortality were as follows: length of hospital stay, respiratory dysfunction, chronic/acute renal failure and septic shock. For adult patients with candidaemia, the variables associated with 30-day mortality were as follows: age, length of hospital stay, respiratory dysfunction, pulmonary infection, cardiovascular disease, chronic/acute renal failure, other invasive catheters, mechanical ventilation, septic shock, *C. albicans* infection, concomitant bacterial infection and haematologic (nonmalignant) disease. The results of the multivariate analysis are listed in Table [5](#Tab5){ref-type="table"}. Because the total numbers of paediatric patients (35 patients) and deaths (3 patients) were very small, multivariable logistic regression analysis was not performed for paediatric patients. Respiratory dysfunction and septic shock were independent predictors of 30-day mortality in all patients and adult patients. The length of hospital stay was a protective factor for 30-day mortality in all patients and adult patients, and other invasive catheters were only the protective factor for 30-day mortality in all patients. The prognostic factors for 30-day mortality in all patients and adult patients were almost the same, and the independent predictors were the same, with no significant differences (Table [5](#Tab5){ref-type="table"}). In addition, we compared the independent protective factors and independent risk factors in this study with those in other studies and found that the protective factors (length of hospital stay and other invasive catheters) in our study were different from those in other studies, while the independent risk factor of septic shock in our study was also identified in some others studies, but the independent risk factor of respiratory dysfunction was not reported in other studies (Table [6](#Tab6){ref-type="table"}). Table 4Factors associated with 30-days mortality by univariate analysis in inpatients with candidaemiaVariableAdult patients (\> 16 years)\
30-days outcome*P*-valueChild patients (0--16 years)\
30-days outcome*P*-valueAll patients\
30-days outcome*P*-valueSurvived\
(*n* = 133)Died\
(*n* = 33)Survived (*n* = 32)Died\
(*n* = 3)Survived (*n* = 165)Died\
(*n* = 36)**Median age(range)60 years(18, 92 years)67 years(29, 86 years)0.001**1 days(1 day, 5 year)1 days (1 day,1 day)0.585**52 years(1 day, 92 years)65 years(1 day, 86 years)0.001**Gender (male:female)72:6120:130.50319:133:00.16491:7423:130.557**Length of hospital stay(days)35.3 ± 42.811.7 ± 9.20.00243.8 ± 20.216.7 ± 8.50.02936.9 ± 39.512.1 ± 9.1\< 0.001**Underlying comorbidities (*n*, %)Gastrointestinal perforation15(11.3)7(21.2)0.1322(6.3)0(0)0.65617 (10.3)7 (19.4)0.125**Respiratory dysfunction28(21.1)27(81.8)\< 0.0011(3.1)2(66.7)\< 0.00129(17.6)29 (80.6)\< 0.001Pulmonary infection54(40.6)22(66.7)0.007**22(68.8)2(66.7)0.941**76(46.1)24(66.7)0.025Cardiovascular disease56(42.1)27(81.8)\< 0.001**3(9.4)0(0)0.579**59 (35.8)27 (75.0)\< 0.001**Neurological diseases41(30.8)13(39.4)0.34722(68.8)2(66.7)0.94163 (38.2)15 (41.7)0.697Gastrointestinal pathology42(31.6)14(42.4)0.2382(6.3)0(0)0.65644(26.7)14 (38.9)0.143Chronic/acute liver disease30(22.6)10(30.3)0.3529(28.1)0(0)0.28739 (23.6)10 (27.8)0.600**Chronic/acute renal failure60(45.1)22(66.7)0.0276(18.8)3(100.0)0.00266 (40.0)22 (61.1)0.001**Haematological malignancy4(3.0)3(9.1)0.1202(6.3)2()0.6566(36.4)5(13.9)0.217Solid tumour12(9.0)3(9.1)0.9900(0)0(0)--12(7.3)3 (8.3)0.826Severe autoimmune diseases12(9.0)3(9.1)0.9900(0)0(0)--12(7.3)3 (8.3)0.826Congenital malformations/syndromes00--5(15.6)1(33.3)0.3655 (3.0)1 (2.8)0.799***Hematologic (nonmalignant)*12(9.0)7(21.2)0.049**9(28.1)1(33.3)0.84921 (12.7)8 (22.2)0.142Diabetes mellitus45(33.8)15(45.5)0.2140(0)0(0)--45(27.3)15 (41.7)0.087HIV/AIDS9(6.8)1(3.0)0.4190(0)0(0)--9(5.5)1 (2.8)0.503Severe trauma12(9.0)3(9.1)0.9902(6.3)0(0)0.56514(8.5)3 (8.3)0.976Risk factors (*n*, %)premature neonates≤36 weeks)^a^------28(87.5)2(66.7)0.51528(93.3)2(100.0)0.706Very low birth weight neonates(\<1500 g)^a^------19(59.4)2(66.7)0.88619(63.3)2(100.0)0.290Presence of CVC57(42.9)13(39.4)0.7186(18.8)1(33.3)0.54663(38.2)14 (38.9)0.937**Other invasive catheters51(38.3)4(12.1)0.004**5(15.6)0(0)0.460**56(33.9)4(11.1)0.007Mechanical ventilation45(33.8)21(63.6)0.002**19(59.4)2(66.7)0.805**64(38.8)23 (63.9)0.006**Receipt of corticosteroids27(20.3)6(18.2)0.7859(18.1)0(0)0.28736 (21.8)6(16.7)0.491Total parenteral nutrition57(42.9)20(60.6)0.06717(53.1)1(33.3)0.51274(44.8)21(58.3)0.142Malnutrition36(27.1)10(30.3)0.7108(25.0)1(33.3)0.75244(26.7)11(30.6)0.635Chemotherapy16(12.0)2(6.1)0.3242(6.3)0(0)0.65618 (10.9)2 (5.6)0.331Abdominal surgery24(18.0)7(21.2)0.6760(0)0(0)--24(14.5)7 (19.4)0.461Hemodialysis22(16.5)8(24.2)0.3030(0)0(0)--22(13.3)8(22.2)0.175ICU/PICU/NICU33(24.8)13(39.4)0.09432(100.0)3(100.0)--65(39.4)16 (44.4)0.576Neutropenia^g^13(9.8)3(9.1)0.9050(0)0(0)--13(7.9)3 (8.3)0.927***Concomitant bacterial infections*59(44.4)21(63.6)0.047**27(84.4)3(100.0)0.46086 (52.1)24 (66.7)0.112**Septic shock8(6.0)28(84.8)\< 0.0011(3.1)2(66.7)\< 0.0019 (5.5)30 (83.3)\< 0.001**Broad-spectrum antibiotics115(86.5)29(87.9)0.83032(100.0)3(100.0)--147(89.1)32(88.9)0.972Treatment with antifungal agents71(53.4)16(48.5)0.61424(75.0)3(100.0)0.32495(57.6)19(52.8)0.599Species, *n* (%)***C. albicans*47(35.3)18(54.5)0.043**16(50.0)0(0)0.09663 (38.2)18 (50.0)0.190*C*. *glabrata*46(34.6)9(27.3)0.42415(46.9)3(100.0)0.07861 (37.0)12 (33.3)0.681*ICU* intensive care unit; *PICU* pediatric intensive care unit, *NICU* neonatal intensive care unit, *CVC* central venous catheter^a^Only neonatal cases were analyzedTable 5Factors associated with 30-days mortality by multivariate analysis^a^VariableAll patientsAdult patientsOdds ratio95% confidence interval*P*-valueOdds ratio95% confidence interval*P*-valueMedian age1.020.973--1.0650.4441.030.957--1.1090.427**Length of hospital stay(days)0.880.809--0.9640.0050.890.802--0.990.032Respiratory dysfunction13.782.254--84.1980.00522.572.014--252.840.011**Pulmonary infection0.680.125--3.6930.6550.980.142--6.7430.982Cardiovascular disease0.650.088--4.7870.6723.360.269--41.9330.347Chronic/acute renal failure2.500.464--13.4250.2871.190.191--7.3920.854**Other invasive catheters0.040.002--0.6950.028**0.040.001--1.2330.066Mechanical ventilation4.590.554--37.9990.15812.560.981--160.7930.052**Septic shock99.9711.997--832.995\< 0.00189.7210.161--792.184\< 0.001**Diabetes mellitus^b^0.120.013--1.0380.054------C. Albicans^b^------3.160.391--25.5050.281Concomitant bacterial infection^b^------4.970.42--58.7420.204Hematologic (nonmalignant)^b^------0.270.018--4.0570.346Total parenteral nutrition^b^------0.060.004--1.060.055ICU/PICU/NICU^b^------0.310.029--3.2590.328*ICU* intensive care unit; *PICU* pediatric intensive care unit, *NICU* neonatal intensive care unit^a^Because the total number of pediatric patients(35 patients) and deaths (3 patients) were very small, multivariable logistic regression analysis was not performed in pediatric patients^b^ Biologically plausible variables with a value of *P* \> 0.1 according to the univariate analyses were not included in the multiple logistic regression modelTable 6Protective factor and predictors of 30-day mortality in others studiesAuthorsCountry or regionstudy periodstudy designsamplesNo of samplesProtective factorPredictors of 30-day mortalityReferenceMa et alChina2009--2011Retrospective,observational,single-center studyCandidemia((130 adultsand 3 children \< 15 years patients)133Presence of CVC37Cortes et alColombia2008--2009Retrospective,observational, multicenter study (seven tertiary-care hospitals)Candidemia(9 days to 87 years patients)131Fluconazole therapyAge, the presence of shock at the time of Candida detection40Wang et alChina2008--2010Retrospective, multicentrestudy(4 tertiary general hospitals)Candidemia(\> 16 years patients)147Antifungal therapy administered before microbiological documentationAbsence of antifungal therapies, receipt of mechanical ventilation and APACHE II score ≥ 2041Tedeschi et alItaly2012--2013Retrospective, observational, multicenter cohort study(39 hospitals)Candidemia (adult patients)232Central-venous-catheter removal and adequate and timely(within 72 h of drawing blood cultures) therapyChronic-obstructive-pulmonary-disease and isolation of C. tropicalis42Li et alChina2010--2014Retrospective, observational,single-center studyCandidemia(\> 18 years patients)190Proven catheter-related candidemiaSevere sepsis or septic shock35Gonzalez-Lara et alMexico2008--2014Retrospective, laboratory-based survey study(two tertiary-care centers hospitals)Candidemia(all patients)149Early CVC withdrawal andempirical antifungal therapySevere sepsis and previous diagnosis of cirrhosis43Jia et alChina2011--2016Retrospective, observational,multicenter study (3 hospitals)Candidemia(15--90 years patients)198ICU admission, catheter-relatedcandidemia, ascites, septic shock and concomitant bacterial infection18Ortega-Loubon et alSpain2007--2016Retrospective, observational, single-cente studyCandidemia(\> 18 years patients)296Prolonged mechanical ventilation, age and low lymphocyte count23Kato et alJapan2011--2016Retrospective, observational,multicenter study (5 hospitals)Candidemia(all patients)289Follow-up blood culture,empiric treatment with fluconazoleAge \> 65 years and SOFA score ≥ 65Ala-Houhala et alFinland2007--2016Retrospective, observationalstudy (2 hospitals)Candidemia(\> 18 years patients)374Severity of underlying illnesses, ICU stay at the onset of candidemia and age \> 65 years4Medeiros et alBrazil2011--2016Retrospective, single-center, observational cohort studyNosocomial candidemia68Older age, severe sepsis and hypotension25Santolaya et alChile2013--2017Prospective, observational multicenter, laboratory-based survey study(26 tertiary care hospitals)Candidemia(all patients)780Mechanical ventilation and previous use of corticosteroids17Alkharashi et alSaudi Arabia2013--2018Retrospective, observational, single-cente studyCandidemia(\> 18 years patients)324Use of broad-spectrum antibiotics and use of central venous catheters24Xiao et alChina2011--2017Retrospective, observational, single-cente studyCandidemia(26--91 years patients)82GCS score, P/F ratio, MAP36This studyChina2013--2019Retrospective, observational, single-cente, cohort studyCandidemia(0--5 years and \> 16 years patients)201Length of hospital stay(days)Respiratory dysfunction and Septic shockThis study*CVC* central venous catheter; *APACHE* Acute Physiology and Chronic Health Evaluation; *ICU* Intensive care unit; *SOFA* Sequential Organ Failure Assessment; *GCS* Glasgow Coma Scale; *P/F ratio* PaO2/FiO2 ratio; *MAP* Mean arterial pressure

Discussion {#Sec7}
==========

This was a 7-year retrospective study of candidaemia in a regional tertiary teaching hospital in Southwest China. We not only analysed the epidemiological characteristics, including the basic information of patients, underlying comorbidities, risk factors, the distributions of Candida species, antifungal agent use, antifungal agent susceptibility results and patient outcomes, but also performed epidemiological comparisons between paediatric patients and adult patients. To our knowledge, this is the first epidemiological comparative study of candidaemia between paediatric and adults patients in Southwest China, which provides reference data for the prevention and treatment of candidaemia in paediatric and adult patients.

Our data showed that there was no significant difference in the sex ratio, length of hospital stay or mortality between adult and paediatric patients (*P* \> 0.05). However, the proportions of underlying comorbidities in paediatric patients, including pulmonary infection, neurological diseases, congenital malformations/syndromes and haematologic (nonmalignant) disease, were higher than those in adult patients (*P* \< 0.05), and the other proportions in adult patients were similar or higher than those in paediatric patients (Table [2](#Tab2){ref-type="table"}). Among the risk factors, only CVC, other invasive catheters and abdominal surgery in adult patients had higher risks than those in paediatric patients (*P* \< 0.05), and other risk factors in children had higher or similar risks as those in adult patients (Table [2](#Tab2){ref-type="table"}). Fewer univariate predictors of poor outcomes were identified for paediatric patients than for adults patients (4 vs 11 predictors), as shown in Table [4](#Tab4){ref-type="table"}. This situation has not been clearly shown in other studies, and more epidemiological investigations are needed for confirmation. The incidence of candidaemia among paediatric patients was significantly higher than that among adults (*P* \< 0.05) (Table [2](#Tab2){ref-type="table"}); however, no significant difference in mortality was found between paediatric patients and adult patients (*P* \> 0.05) (Table [2](#Tab2){ref-type="table"}) in contrast to other studies \[[@CR16], [@CR17]\].

Our data showed that the median age of patients with candidaemia and the proportion of males were similar to those in other studies \[[@CR8], [@CR18]--[@CR23]\]. Moreover, our study showed that the patients with candidaemia were hospitalised mostly in internal medicine wards, which is different from other studies that reporting hospitalisation mainly in ICU wards \[[@CR8], [@CR22], [@CR24]--[@CR27]\], but similar to other studies \[[@CR28]--[@CR31]\]. This phenomenon may be related to the demographic characteristics of the inpatients in our hospital, most of whom had more than two underlying diseases and were hospitalised in internal medicine wards. However, the incidence of candidaemia was still the highest in the ICU, similar to other studies \[[@CR8], [@CR30]--[@CR34]\]. In accordance with other studies \[[@CR17]--[@CR19], [@CR24], [@CR25], [@CR30], [@CR32], [@CR35], [@CR36]\], *C. albicans* was the most common cause of candidaemia in the whole hospital, but the proportion of non-*C. albicans* infections was higher than that of *C. albicans* infections. Moreover, the proportions of *C. glabrata* in surgical, internal medicine and paediatric wards were the highest, which is different from other studies in China \[[@CR18], [@CR19], [@CR35]--[@CR37]\] but similar to other studies in other countries \[[@CR4], [@CR22], [@CR27], [@CR29], [@CR32]\]. This may be due to the large number of elderly patients and the increasing use of azole antifungal agents.

Our data showed that the incidence of candidaemia increased from 0.20 episodes/1000 admissions in 2013 to 0.37 episodes in 2016 and then dropped to 0.26 between 2017 and 2019. The change in the annual incidence rate was mainly due to the change in the incidence rate in paediatric patients. The reasons may be due to the gradual easing of restrictions of China's two-child policy since 2013. The number of geriatric pregnant women has increased annually, resulting in an increase in the incidence of neonatal diseases. The change trend was similar to that reported by Oeser et al. \[[@CR38]\]. The overall morbidity and 30-day mortality in ICUs and hospitals in this study were similar to those in another hospital in this region of China \[[@CR18]\], but lower than those in hospitals in other regions of China \[[@CR35], [@CR37]\] and other countries \[[@CR5], [@CR8], [@CR16], [@CR20], [@CR21], [@CR23], [@CR25], [@CR30]\]. The overall mortality rate of candidaemia has been reported to be 20--49% globally \[[@CR39]\], and the mortality rate was 20.4% in our hospital, which is low compared to the global rate. This may be because the demographic characteristics and underlying diseases of patients in this region are different from those in other regions or countries, and few severe patients were admitted to our hospital.

With regard to resistance, resistance to FCA, ITR and VRC were common in *C. albicans* and non-*C. albicans* species (Table [3](#Tab3){ref-type="table"}). In our study, AMB and 5-FC were highly active against all Candida species. In paediatric patients, the resistance rate of ITR was higher than that in adult patients, but the resistance rates of FCA and VRC were lower than those in adult patients; however, and the resistance rate of Candida species was no significant difference in satisfaction between paediatric and adult patients(*P* \> 0.05). Moreover, FCA was highly active against all Candida species in paediatric patients and could be used in paediatric patients with candidaemia as a first-line agent. In the whole hospital, the resistance rate to azole was higher than those reported in other regions \[[@CR18], [@CR19], [@CR36]\] and countries \[[@CR17], [@CR19], [@CR25], [@CR29], [@CR30], [@CR34]\]. This may be related to the long-term use of empirical prophylactic drugs by clinicians. Therefore, it was necessary to conduct an epidemiological analysis of antifungal agent susceptibility and guide clinicians to choose the rational antifungal agents to avoid the continuous increase in resistance rates.

In this study, septic shock was an independent predictor of 30-day mortality; which has been reported in many other studies \[[@CR18], [@CR35]\]. However, the other factors reported here have rarely been reported in other studies \[[@CR35], [@CR40]--[@CR43]\], possibly because the demographic characteristics, underlying diseases and risk factors of the patients in our study were different from those in other studies; which may be the reason that the independent predictors and protective factors in this study were different from those in other studies \[[@CR5], [@CR35], [@CR40]--[@CR43]\]. The independent predictors and protective factors in different regions and countries are shown in Table [6](#Tab6){ref-type="table"}.

The limitations of this study must be acknowledged. First, this was a single-centre retrospective study, and the total number of patients(166 adult and 35 paediatric patients) were small. Our data might be influenced by the number of patients, the level of medical intervention, and the distribution of patient types. Second, due to technical limitations of the clinical microbiology laboratory and the impact of hospital policies, no data on echinocandins were available in our hospital. Therefore, the results may not be generalizable to all patients with candidaemia in China.

Conclusion {#Sec8}
==========

*C. albicans* was the main Candida species, but *C. glabrata* has become the second most common species in this region. FCA was the main antifungal agent for paediatric patients. AMB and 5-FC were highly active against all Candida species. The morbidity and mortality rates in elderly patients were the highest. Respiratory dysfunction and septic shock were independent predictors of 30-day mortality. Further multi-centre studies on candidaemia in different geographical regions in all patients should be conducted to help infection specialists assess the distribution and trends in patients with suspected fungal infections.

BSI

:   Bloodstream infection

ICU

:   Intensive care unit

PICU

:   Paediatric intensive care unit

NICU

:   Neonatal intensive care unit

USA

:   United States of America
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:   American type culture collection

MALDI-TOF MS

:   Matrix-assisted laser desorption/ionization-time of flight mass spectroscopy

FCA

:   Fluconazole

ITR

:   Itraconazole

AMB

:   Amphotericin B

VRC

:   Voriconazole
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:   Flucytosine

CVC

:   Central venous catheter
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:   Odds ratio
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